#Biosimilars Market Share

[healthcarehubhh]

Biosimilar Pipeline Analysis Market will grow at highest pace owing to increasing opportunity in oncology segment.

Biosimilar pipeline analysis refers to the development and evaluation of biopharmaceutical products that are similar to already approved biological drugs (reference products). Biosimilars demonstrate similarity in physicochemical characteristics, efficacy, safety and immunogenicity with the reference biologic drug. The development of biosimilars helps increase patient access and lowers health care costs. Key product types in the biosimilar pipeline include monoclonal antibodies, recombinant hormones/ growth factors, glycopeptides and peptides. Biosimilars offer clinical effectiveness comparable to reference products at a lower cost, thereby benefitting patients and public health systems. The Global Biosimilar Pipeline Analysis Market is estimated to be valued at US$ 29.4 Bn in 2024 and is expected to exhibit a CAGR of 17% over the forecast period 2023 to 2030. Key Takeaways Key players operating in the Biosimilar Pipeline Analysis are Pfizer Inc. (AC. Hospira). Pfizer is a leading player with a strong pipeline of oncology and anti-inflammatory biosimilars. Oncology is the largest application segment in the biosimilar pipeline market. Many biologic drugs facing patent expiry in oncology offer significant commercial opportunities for biosimilar developers. Increased incidence of cancer worldwide is also propelling demand. Technological advancements such as monoclonal antibody engineering, automation of mammalian cell culture processes and analytical characterization methods have improved the speed and success rate of biosimilar development. Advanced analytics aid in more accurate profiling and higher similarity assessment of biosimilar candidates. Market Trends Emerging markets in Asia Pacific and Latin America offer lucrative growth opportunities for biosimilar developers due to their large patient populations and growing healthcare budgets. Countries like China, India, Brazil and Mexico are actively working to expand patient access to affordable biologics through biosimilars. Biosimilar approval pathways are evolving to strategic partnerships between originators and biosimilar companies. Collaboration models such as licensing agreements are gaining precedence over antagonistic approaches and patent litigation, facilitating timely market entry of affordable biosimilars. Market Opportunities Increased penetration of biosimilars for anti-TNF drugs to treat autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease. Biosimilars of anti-TNF biologics enjoy highest success rates and market adoption. Strong pipeline of oncology biosimilars facing patent expiry over 2023-2030 including bevacizumab, trastuzumab, rituximab, which could realize combined global sales potential exceeding US$25 billion.

[aimarketresearch]

Biosimilar Market Size, Share, Key Growth Drivers, Trends, Challenges and Competitive Landscape

Data Bridge Market research has recently issued comprehensive industry research on Global Biosimilar Market which includes growth analysis, regional marketing, challenges, opportunities, and drivers analysed in the report.

Besides, Biosimilar market report studies market growth opportunities and restraining factors. The geographical division of this market analysis report offers data that gives an idea of the revenue of the companies and sales figures of the market growth. The market report also contains the drivers and restraints for the Biosimilar market that are obtained with the help of SWOT analysis, and also shows all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands with their systemic company profiles, that are driving the market.

Access Full 350 Pages PDF Report @

Data Bridge Market Research analyses that the global biosimilar market which was USD 37,270.20 million in 2022, is expected to reach USD 343,520.90 million by 2030, and is expected to undergo a CAGR of 32.00% during the forecast period 2023-2030. “Oncology” dominates the product segment of the global biosimilar market owing to the owing to the increase in number of research studies, increasing research and development activities by key players focused on oncology and advancements in healthcare technologies. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Key Questions Answered with this Study

1) What makes Biosimilar Market feasible for long term investment?

2) Know value chain areas where players can create value?

3) Teritorry that may see steep rise in CAGR & Y-O-Y growth?

4) What geographic region would have better demand for product/services?

5) What opportunity emerging territory would offer to established and new entrants in Biosimilar Market?

6) Risk side analysis connected with service providers?

7) How influencing factors driving the demand of Biosimilarin next few years?

8) What is the impact analysis of various factors in the Global Biosimilar Market growth?

9) What strategies of big players help them acquire share in mature market?

10) How Technology and Customer-Centric Innovation is bringing big Change in Biosimilar Market?

Some of the major players operating in the global biosimilar market are:

Novartis AG (Switzerland)

 Orion Pharma AB (Sweden)

 Pfizer Inc. (U.S.)

Samsung Bioepis. (South Korea)

 Coherus BioSciences, Inc. (U.S.)

 Amgen Inc. (U.S.)

Eli Lilly and Company (U.S.)

 Takeda Pharmaceutical Company Limited. (Japan)

 Bristol-Myers Squibb Company (U.S.)

 Merck KGaA (Germany)

 Teva Pharmaceutical Industries Ltd. (U.S.)

 Biocon. (India)

 Bayer AG (Germany)

 AbbVie Inc. (U.S.)

 Allergan (Ireland)

 Dr. Reddy’s Laboratories Ltd. (India)

 Boehringer Ingelheim International GmbH. (Germany)

 Biogen (U.S.)

Browse Trending Reports:

Prenatal Testing And New Born Screening Market

Rapid Oral Fluid Screening Device Market

North America Eclinical Solutions Market

Medical Tuning Fork Market

North America Cbct Dental Imaging Market

Myopia Treatment Market

Induced Pluripotent Stem Cells Market

Pneumococcal Vaccine Market

Dupuytrens Disease Market

Mitogen Activated Protein Kinase Mapk Inhibitors Therapeutics Market

Neonatal Seizures Drugs Market

Chikungunya Treatment Market

Sickle Cell Disease Treatment Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com

[kenresearch1]

Biosimilars Unleashed: The Future of Healthcare in the US

Buy Now

What is the Size of US Biosimilar Industry?

US Biosimilar Market is expected to grow at a CAGR of ~ % between 2017-2022 and is expected to reach ~USD Bn by 2028. Biosimilars enhance patient access to essential treatments, especially in therapies with high demand, like oncology, by providing more affordable options. Additionally, Growing evidence of biosimilars' comparable efficacy and safety fosters trust among healthcare professionals, driving adoption.

Click here to Download a sample Report

Biosimilars offer cost savings compared to originator biologics, addressing the need for affordable healthcare solutions in the face of rising medical costs. Favorable regulatory frameworks, like the BPCIA, streamline biosimilar approval processes, encouraging manufacturers to invest in development.

Furthermore, The expiration of patents for numerous reference biologics creates opportunities for biosimilar entry, leading to increased competition and market expansion. Pharmaceutical companies are investing in biosimilar R&D and production, expanding the pipeline and market availability. Supportive healthcare policies and reimbursement models incentivize biosimilar adoption, creating a favorable environment for market growth.

US Biosimilar Market by drug class

The US Biosimilar market is segmented by Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory agents and Others. Based on drug class, Monoclonal Antibodies segment dominates the bio similar market in 2022.

Monoclonal antibodies have diverse applications across various therapeutic areas. From cancer treatment to autoimmune diseases, biosimilar Mabs addressed a wide range of medical needs, leading to a broad and growing market. Biosimilars, with their potential for cost savings while maintaining comparable efficacy and safety, gained significant attention as viable alternatives.

US Biosimilar Market by application

In US Biosimilar market, they are segmented by application into Oncology, Blood disorders, Chronic diseases and autoimmune conditions and Others. On the basis of application, Oncology segment was the dominant in 2022.

The increasing prevalence of cancer and the high cost of traditional biologics used in oncology treatment have created a strong incentive for the adoption of biosimilars. Biosimilars offer the potential to provide similar therapeutic outcomes at a lower cost, making them an attractive option for both healthcare providers and patients.

Additionally, the rigorous clinical trials and regulatory processes that biosimilars undergo to gain approval provide reassurance to healthcare professionals and patients regarding their safety and efficacy. This has led to increased acceptance and adoption of biosimilars in oncology.

US Biosimilar by Region

The US Biosimilar market is segmented by Region into North, East, West and South. In 2022, the dominance region is North region in US Biosimilar market.

The North region benefits from a concentration of healthcare providers and academic institutions that are at the forefront of adopting and integrating biosimilars into their treatment protocols. These institutions are more likely to have the expertise to evaluate and incorporate biosimilars effectively, driving their adoption among healthcare professionals and patients.

Click here to Download a Custom Report

Competition Scenario in US Biosimilar Market

The US biosimilar market has witnessed an evolving competitive landscape, with several key players competing for market share. Prominent pharmaceutical companies such as Amgen, Pfizer, Sandoz (Novartis), and Boehringer Ingelheim have been actively involved in developing and marketing biosimilar products. These established players have utilized their expertise in biologics and significant resources to navigate the regulatory landscape and compete effectively.

The competition in the US biosimilar market is characterized by a balance between established pharmaceutical giants and emerging biotech companies. While the major players possess the advantage of resources and experience, smaller biotech firms are also contributing to the market with innovative approaches and niche biosimilar offerings.

What is the Expected Future Outlook for the Overall US Biosimilar Market?

The US Biosimilar market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Billion by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. The US biosimilar market is likely to experience significant growth in the coming years, driven by several factors. Biosimilars are biologic drugs that are highly similar to already approved reference biologics. They offer potential cost savings, increased competition, and improved patient access to crucial treatments.

Firstly, the regulatory environment is becoming more favorable for biosimilars. The Biologics Price Competition and Innovation Act (BPCIA) established a pathway for biosimilar approval in the US, allowing for a smoother regulatory process. As more biosimilars receive approval, competition in the market is expected to intensify.

Secondly, patents for several blockbuster biologics are expiring or have already expired. This creates opportunities for biosimilar manufacturers to enter the market with more affordable alternatives, offering healthcare systems and patients a choice in treatment options.

Thirdly, as healthcare costs continue to rise, biosimilars present an attractive solution for reducing expenses. Their potential to offer cost savings without compromising therapeutic efficacy could lead to increased adoption by healthcare providers, insurers, and patients alike.

Physician and patient education are crucial, as misconceptions about biosimilars' safety and effectiveness might hinder their adoption. Additionally, legal and market access barriers, including patent litigation and complex distribution systems, could slow down the growth of the biosimilar market.

The biosimilar market witness consolidation as larger pharmaceutical companies acquire or partner with smaller biotech firms to bolster their biosimilar portfolios. This will lead to more resources being devoted to biosimilar development and marketing. Changes in healthcare policies, such as reimbursement models and value-based care initiatives, can influence the biosimilar market's growth. Favourable policies that incentivize biosimilar adoption drives their market growth.

[joeypetter]

Biosimilars Market Size 2022 Industry Recent Developments and Technology, Size, Trends, Growth, and Forecast Research Report 2030| By R&I

The report is titled as ‘Biosimilars Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the biosimilars market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Biosimilars market is expected to grow with a significant rate in the near future.

The global biosimilars market in 2020 is estimated for more than US$ 11,036.2 Mn and expected to reach a value of US$ 1,09,501.8 Mn by 2028 with a significant CAGR of 33.5%.

Request a Sample Copy of this Report @: https://reportsandinsights.com/sample-request/1243

Biosimilars Market Dynamics

Patent expiration in the biological drug industry is the major factor driving the growth of global biosimilars market. Moreover, the introduction of clear regulatory pathways for the introduction of biosimilars to the market by many countries is further encouraging biosimilar development. For instance, recently India and Canada introduced regulations for approval of biosimilar drugs in respective countries. However, unlike generic chemical entities, producing identical copies of innovator cell-based drugs is impossible and takes more time, which is the biggest challenge for the growth of global biosimilars market. Biologics are produced by cells in culture or whole organisms, which are inherently more variable than chemical synthesis methods.     

Biosimilars Market Regional Overview

On the basis of region, the global biosimilars market is segmented into six regions namely North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. North America biosimilars market is expected to be the most dominating market throughout the forecast period due to due to the expiry of patents for blockbuster biological drugs. The presence of key players in Europe makes it second-largest market for biosimilars. Asia Pacific biosimilars market is expected to witness delayed growth due to relatively long patent term for biological drugs

MMC Overview

The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

A research report on the biosimilars market by Reports and Insights is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support market and the factors that are acting as impedance for the growth of the market. Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Wish to Know More About the Study? Click here to get a Report Description: https://reportsandinsights.com/report/global-biosimilars-market

Biosimilars Market Key Players

Some of the key participating players in global Biosimilars market are:

    Pfizer

    Sandoz International

    Teva Pharmaceuticals

    Amgen

    Biocon

    Dr. Reddy’s Laboratories

    Celltrion

    Samsung Biologics

    Synthon Pharmaceuticals, Inc.

    LG Life Sciences

    Biocon

    Hospira

    Merck Serono (Merck Group)

    Biogen Idec Inc.

    Genentech (Roche Group)

Biosimilars Market Segmentation

The global Biosimilars market is segmented on the basis of product type, manufacturing, diseases, and region.

By Product Type

    Recombinant Non-Glycosylated Proteins

    Recombinant Human Growth Hormone (RHGH)

    Granulocyte Colony-Stimulating Factor (Filgrastim)

    Insulin

    Interferons

     Interferon-Beta

     Interferon-Alpha

    Recombinant Glycosylated Proteins

    Erythropoietin (EPO)

    Monoclonal Antibodies (MABS)

     Infliximab

     Rituximab

     Adalimumab

     Other Monoclonal Antibodies

    Follitropin

    Recombinant Peptides

    Glucagon

    Calcitonin

By Type of Manufacturing

    In-House Manufacturing

    Contract Manufacturing

By Disease

    Oncology

    Chronic Diseases

    Autoimmune Diseases

    Blood Disorders

    Growth Hormone Deficiency

    Infectious Diseases

    Other Diseases

By Region

    North America

    Latin America

    Europe

    Asia Pacific

    Middle East

    Africa

To view Top Players, Segmentation and other Statistics of Biosimilars Industry, Get Sample Report @: https://reportsandinsights.com/sample-request/1243

About Reports and Insights:

Reports and Insights is one of the leading market research companies which offers syndicate and consulting research around the globe. At Reports and Insights, we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Neil Jonathan

1820 Avenue M, Brooklyn

NY 11230, United States

+1-(718) 312-8686

Find Us on LinkedIn: www.linkedin.com/company/report-and-insights/

View Latest Market Updates At: https://marketsresearchanalytics.com

[insightslicelive]

Biosimilar Market Growth Opportunities Investment Analysis Report 2022-2032 | Amgen Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd.

Biosimilar Market Growth Opportunities Investment Analysis Report 2022-2032 | Amgen Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd.

The Biosimilar Market research report provides detailed observation of several aspects, including the shift in rate of growth, regional scope and recent developments by the primary market players. The report offers Porter’s Five Forces, PESTLE analysis to provide a complete research study on the global Biosimilar market. The research study discusses about important market strategies, future…

[health-views-updates]

Biological Safety Testing Products and Services Market 2024 | Upcoming Trend in Biological Safety Testing Products and Services Industry by an Expert

The global biological safety testing products and services market is on a robust growth trajectory, valued at $4.42 billion in 2023 and projected to reach $10.51 billion by 2032. This remarkable growth reflects a compound annual growth rate (CAGR) of 10.10% over the forecast period from 2024 to 2032, driven by the increasing demand for safety and efficacy testing across the biopharmaceutical and healthcare sectors.

Biological safety testing is essential for ensuring that medical products, including pharmaceuticals, vaccines, and medical devices, meet stringent safety and efficacy standards before reaching the market. The market encompasses a wide range of testing services, including sterility testing, endotoxin testing, and biocompatibility assessments, all critical for regulatory compliance.

Key Market Drivers

Increasing Biopharmaceutical R&D Activities: The rising investment in biopharmaceutical research and development is a significant factor propelling the market. As the industry focuses on innovative therapies, including monoclonal antibodies, gene therapies, and cell therapies, the need for rigorous biological safety testing becomes paramount. These testing services help ensure that new products are safe for human use, fostering trust in the healthcare system.

Regulatory Compliance and Safety Standards: Stringent regulatory requirements from agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global health authorities are driving the adoption of biological safety testing services. Compliance with these regulations is critical for companies looking to launch new medical products, creating a steady demand for testing services that ensure product safety and efficacy.

Growing Concerns About Contamination and Quality Assurance: The increasing prevalence of product recalls due to contamination and safety issues has heightened awareness about the importance of biological safety testing. Companies are now more vigilant in their quality assurance processes, recognizing that thorough testing is essential to maintain product integrity and safeguard public health.

Expansion of the Healthcare Sector: The ongoing expansion of the healthcare sector, particularly in emerging markets, is creating new opportunities for biological safety testing services. With the growth of healthcare facilities and the increasing production of biologics and biosimilars, the demand for reliable testing solutions is expected to rise significantly.

Access Free Sample Report: https://www.snsinsider.com/sample-request/4483 

Challenges and Opportunities

While the market shows strong potential, it faces challenges such as the high cost of testing services and the need for specialized expertise. However, advancements in technology, including automation and digitalization, are likely to streamline testing processes, reduce costs, and enhance the accuracy of results.

Moreover, the increasing adoption of 3D cell culture systems and organ-on-a-chip technologies offers opportunities for innovative testing solutions. These advancements are expected to improve the efficiency and effectiveness of biological safety testing, providing companies with the tools they need to ensure product safety.

Regional Insights

North America holds the largest share of the biological safety testing market, driven by the presence of leading biopharmaceutical companies, advanced research facilities, and stringent regulatory standards. Europe follows closely, with significant investments in healthcare and biotechnology sectors. The Asia-Pacific region is expected to experience the highest growth rate during the forecast period, supported by the expansion of healthcare infrastructure and increasing research activities in countries such as China, India, and Japan.

Future Outlook

As the demand for innovative biopharmaceutical products continues to rise, the biological safety testing products and services market is set for significant growth. With a projected CAGR of 10.10% from 2024 to 2032, the market is poised to see substantial advancements in testing technologies, helping to meet the increasing demand for safety and efficacy in healthcare products.

In conclusion, the biological safety testing products and services market is entering a dynamic phase of growth, with a valuation expected to rise from $4.42 billion in 2023 to $10.51 billion by 2032. This growth is driven by regulatory compliance, the expansion of biopharmaceutical R&D, and the need for rigorous quality assurance in an increasingly complex healthcare landscape

Other Trending Reports

Dental Suction Systems Market Size

Cosmeceuticals Market Size

Cell Therapy Market Size

Growth Hormone Deficiency Market Size

[mordorintelligencemarketresearch]

The Pharmaceutical Glass Vials and Ampoules Market: Insights and Future Trends 

Introduction 

The pharmaceutical glass vials and ampoules market plays a crucial role in the global healthcare landscape. These glass containers are essential for storing and preserving medications, vaccines, and other biologics, ensuring their integrity and effectiveness. As the pharmaceutical industry continues to expand, understanding the dynamics of this market is vital for stakeholders. 

Market Overview 

Current Market Size and Growth 

The Pharmaceutical Glass Vials and Ampoules market is projected to be valued at approximately USD 14.82 billion in 2024 and is expected to grow to around USD 20.73 billion by 2029. This growth reflects a compound annual growth rate (CAGR) of 6.94% during the forecast period from 2024 to 2029. This growth is largely driven by an increase in drug production and the rising demand for biologics and sterile products. 

Key Drivers of Growth 

Rising Biologics Demand: The increasing prevalence of chronic diseases and the growing biologics sector are major factors driving the demand for glass vials and ampoules. These products are preferred for their ability to maintain the stability and efficacy of sensitive formulations. 

Safety and Stability: Glass is inherently inert and non-reactive, making it an ideal material for pharmaceutical applications. Its ability to preserve the integrity of the contents, especially in sterile environments, boosts its popularity. 

Growing Vaccine Production: The COVID-19 pandemic has led to a surge in vaccine development and production, significantly impacting the demand for glass containers like vials and ampoules. 

Increasing Investment in R&D: Pharmaceutical companies are investing heavily in research and development, leading to the production of more complex and sensitive drugs that require specialized packaging solutions. 

Regional Insights 

North America 

North America is a leading market for pharmaceutical glass vials and ampoules, driven by a well-established pharmaceutical industry and stringent regulatory standards. The region's focus on innovation and quality assurance bolsters the demand for high-performance glass containers. 

Europe 

Europe also holds a significant share of the market, with countries like Germany and France leading in pharmaceutical production. The rising focus on biologics and biosimilars is further propelling market growth in this region. 

Asia-Pacific 

The Asia-Pacific region is expected to experience the highest growth rate, fueled by rapid industrialization, increasing healthcare expenditures, and a growing population. Emerging markets such as China and India are becoming key players in pharmaceutical manufacturing, driving the demand for glass vials and ampoules. 

Challenges Facing the Industry 

While the pharmaceutical glass vials and ampoules market is expanding, several challenges must be addressed: 

Cost of Production: The high cost of glass manufacturing can limit profitability, especially for smaller companies in a price-sensitive market. 

Regulatory Compliance: Adhering to stringent regulations regarding quality and safety can be complex and resource-intensive for manufacturers. 

Competition from Alternative Materials: The rise of alternative packaging materials, such as plastics and polymers, poses a potential threat to the glass market. 

Future Outlook 

The pharmaceutical glass vials and ampoules market is poised for continued growth, driven by several key trends: 

Sustainability Initiatives: As the industry moves toward sustainable practices, manufacturers are exploring eco-friendly production methods and recyclable glass solutions. 

Technological Advancements: Innovations in glass production, including improvements in design and functionality, will enhance the performance of vials and ampoules, catering to evolving market needs. 

Expansion in Emerging Markets: Increased investment in healthcare infrastructure in developing regions will create new opportunities for growth in the pharmaceutical glass packaging sector. 

Conclusion 

The pharmaceutical glass vials and ampoules market is on an upward trajectory, driven by rising demand for biologics, stringent safety standards, and ongoing innovations in packaging solutions. Stakeholders who focus on quality, sustainability, and technological advancements will be well-positioned to capitalize on the opportunities that lie ahead in this essential industry.    For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence: https://www.mordorintelligence.com/industry-reports/pharmaceutical-glass-vials-and-ampoules-market 

[tamanna31]

Pharmacovigilance Market Size, Share, Growth, Analysis Forecast to 2030

Pharmacovigilance Industry Overview

The global pharmacovigilance market size was estimated at USD 7.32 billion in 2023 and is anticipated to grow at a CAGR of 6.8% from 2024 to 2030.

The rising incidence of Adverse Drug Reactions (ADRs) owing to drug abuse and the prevalence of diseases that require a combination of drugs are the major growth drivers for the market. In addition, an upward shift in the production of novel drugs and the presence of stringent government regulatory frameworks for drug safety are significantly boosting the market growth. For instance, the U.S. FDA and the EU’s European Medical Agency (EMA) formulate regulatory guidelines for all phases of clinical trials. Moreover, advancements in the development of ADR databases and information systems have enabled accurate reporting of information, which can be further utilized by research professionals for prospective clinical studies, thereby fueling overall growth.

Gather more insights about the market drivers, restrains and growth of the Pharmacovigilance Market

A rise in the incidence of chronic diseases, such as cancers, diabetes, and cardiovascular & respiratory disorders, has led to an increase in drug consumption worldwide. According to a WHO report on pharmaceutical consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in nonhospital setups. Increasing drug development activities in areas such as personalized medicines, biosimilars, orphan drugs, and companion diagnostics, along with adaptive trial designs, is projected to boost the demand for pharmacovigilance services in the coming years.

Furthermore, the increasing incidence of ADR and drug toxicity is fueling the market growth. According to the National Center for Biotechnology Information (NCBI), approximately 5% of total hospitalizations in a year are due to ADR in Europe. Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious Adverse Drug Reactions (ADRs) in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade.

Browse through Grand View Research's Healthcare IT Industry Research Reports.

The global personalized medicine market was valued at USD 529.28 billion in 2023 and is projected to grow at a CAGR of 8.20% from 2024 to 2030.

The global medical writing market size was valued at USD 3.8 billion in 2022 and is expected to expand at a CAGR of 10.46% from 2023 to 2030.

Key Pharmacovigilance Company Insights

The market is characterized by a few notable players, including Accenture, IQVIA, Cognizant, Aris Global, and IBM Corporation. These manufacturers are actively utilizing strategic initiatives such as mergers and acquisitions to strengthen their market positions. For instance, in October 2023,  IQVIA strategically collaborated with argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions.

"We look forward to collaborating closely with IQVIA on this important business need. We aim to innovate in all that we do and IQVIA’s technology-enabled PV services and solutions will allow for efficient data integration as we work to bring new treatment options to autoimmune patients”.

- Tim Van Hauwermeiren, CEO, argenx.

In November 2022, Linical Americas (a U.S. subsidiary of The Linical Group) and Science 37 Holdings, Inc. announced a partnership to enable the deployment of hybrid and fully decentralized trials. This partnership will provide enhanced access to Linical’s offerings.

“By partnering with Linical, we have an important new ally in our mission to accelerate clinical research and enable universal access for patients,” “Our technology-enabled Metasite will empower and enhance Linical’s solutions, helping patient’s access new life-changing treatments quicker, in the largest and most prevalent therapeutic areas.”

- ”David Coman, Chief Executive Officer of Science 37

Recent Developments

In March 2023, ICON plc and LEO Pharma announced partnerships to impel execution of clinical trials in medical dermatology space.

“We’ve been exploring several outsourcing models but found a hybrid sourcing model to be the most efficient. Partnering with ICON supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business through scalability and flexibility. “ICON’s wealth of services and leading position in clinical development will support LEO Pharma’s R&D strategy building on driving innovation through partnerships and support staying competitive.”

- Jörg Möller, Executive Vice President and head of Global R&D at LEO Pharma

In February 2023, Parexel International Corporation announced the launch of Expert Series-New Medicines, Novel Insights. The series features latest insights from company’s cross-functional experts postanalysis of trends that impact drug development and evidence-based guidance for the biopharmaceutical industry.

“Cutting-edge medicines are becoming more personalized and precise across the therapeutic landscape, while the process to develop those therapies is reaching new heights of complexity. “Parexel’s New Medicines, Novel Insights research series offers expert-led guidance to deliver on the promise of patient-focused drug development and bring impactful treatments to patients more rapidly.”

- Amy McKee, MD, Chief Medical Officer and Head of Oncology Center of Excellence

Key Pharmacovigilance Companies

The following are the leading companies in the pharmacovigilance market These companies collectively hold the largest market share and dictate industry trends

Accenture

IQVIA Inc.

Cognizant

Clinquest Group B.V. (Linical Americas)

IBM

Laboratory Corporation of America Holdings

ArisGlobal

Capgemini

ITClinical

ICON plc.

TAKE Solutions Limited

Parexel International (MA) Corporation

Wipro

United BioSource LLC

BioClinica Inc. (Clario)

ClinChoice (formerly FMD K&L

Order a free sample PDF of the Pharmacovigilance Market Intelligence Study, published by Grand View Research.

[shubhampawrainfinium]

Prefilled Syringes: A Game-Changer for Drug Delivery

Introduction

The Prefilled Syringes Market is experiencing rapid growth as healthcare providers and patients increasingly prefer prefilled syringes over traditional vial-and-syringe methods. Prefilled syringes offer convenience, accuracy, and safety, reducing the risk of dosing errors and contamination. They are used for a variety of therapeutic applications, including vaccines, biologics, and anticoagulants. The market is expanding globally, driven by increasing chronic disease prevalence, technological advancements in injectable drugs, and the growing demand for self-administration.

Market Dynamics

Drivers

Growing Prevalence of Chronic Diseases: The rise in conditions such as diabetes, cardiovascular diseases, and autoimmune disorders has increased the demand for injectable medications, fueling the growth of the prefilled syringes market.

Patient Convenience and Safety: Prefilled syringes offer a more convenient and safer alternative to traditional methods, especially for patients requiring frequent injections.

Challenges

High Production Costs: The manufacturing of prefilled syringes requires stringent quality control and high precision, leading to increased production costs.

Regulatory Compliance: Prefilled syringes must meet rigorous regulatory standards, particularly for biological drugs, creating challenges for manufacturers.

Opportunities

Biologics and Biosimilars: The growing market for biologic drugs presents significant opportunities for the prefilled syringes market, as these drugs often require injectable delivery.

Homecare and Self-Administration: With the increasing demand for home healthcare solutions, prefilled syringes are becoming more popular for self-administration of medications, offering a major growth avenue.

Regional Analysis

North America: The largest market for prefilled syringes, driven by the high prevalence of chronic diseases and advanced healthcare infrastructure.

Europe: Europe is a major market, with countries like Germany and the U.K. leading in the adoption of biologics and injectable therapies.

Asia-Pacific: The region is witnessing rapid growth due to rising healthcare expenditure, increasing chronic disease burden, and expanding access to healthcare in countries like China and India.

Sample pages of Report: https://www.infiniumglobalresearch.com/form/193?name=Sample

Market Segmentation

By Material:

Glass Syringes: Traditionally dominant, but gradually being replaced by plastic due to concerns about breakage and contamination.

Plastic Syringes: Gaining popularity due to their lightweight and durable nature.

By Application:

Diabetes: Prefilled syringes are widely used for insulin administration.

Vaccines: Increasingly used for vaccine delivery due to their convenience and precision.

Competitive Landscape

How much share do large players hold? Companies like BD (Becton, Dickinson and Company), Gerresheimer, and SCHOTT dominate the market, holding a significant share due to their established presence and advanced manufacturing capabilities.

Do big players control the price? Yes, large players with sophisticated manufacturing processes and partnerships with pharmaceutical companies have significant control over pricing in the market.

Do small and mid-size companies challenge the large companies domestically? While smaller companies are entering the market with niche products and regional focus, they face challenges in competing with the scale and pricing power of larger players.

Report Overview : https://www.infiniumglobalresearch.com/market-reports/global-prefilled-syringes-market

Future Outlook

Does new product development really help companies? Yes, innovations in materials, such as plastic prefilled syringes, and the development of safety features like needle shields have helped companies gain market share.

Do sustainable products hold strong customers' minds? Sustainability is becoming increasingly important, with healthcare providers and patients showing a preference for eco-friendly packaging and materials in prefilled syringes.

Conclusion

The prefilled syringes market is poised for substantial growth, driven by increasing chronic disease prevalence, the rise of biologics, and the growing demand for patient convenience. While challenges around cost and regulatory compliance remain, innovations in materials and safety features are expected to drive the market forward.

[healthcaremarketanalysis]

Prefilled Syringes Market worth $13.1 billion by 2030 driven by Rising Chronic Illness Rates | MarketsandMarkets™

The global Prefilled Syringes Market is expected to grow from USD 7.1 billion in 2024 to USD 13.1 billion by 2030, at a CAGR of 10.8%. Prefilled syringes are a convenient and precise medical device for delivering single doses of medication, reducing drug waste and extending product lifespan. They are increasingly adopted due to rising chronic illnesses, demand for effective drug delivery, and regulatory support for safer injection methods. Commonly used for biologics, vaccines, and other therapeutic products, these syringes enhance patient safety by minimizing errors and improving dosing accuracy. The market is expanding due to the prevalence of chronic diseases and the growing trend towards self-administration. However, challenges such as product recalls and competition from alternative drug delivery methods may impact growth. The market is driven by rising demand for biologics and biosimilars, with glass and single-chamber syringes expected to dominate. North America leads the market due to its advanced healthcare infrastructure and high demand for precise drug delivery solutions. Key players include BD, Gerresheimer AG, SCHOTT, and West Pharmaceutical Services, among others.

Download PDF Brochure:

Prefilled Syringes Market Dynamics

Drivers

· Rising target disease population

· Rapid growth in generic products

· Rising adoption of self-medication and digitalization

· Affordable cost with increased efficiency of prefilled syringes

· Technological advancements

Restraints

· Dearth of prefilled syringes with integrated safety features

Opportunities

· Growing healthcare infrastructure across emerging markets

· Surge of biologics and biosimilars in biopharma industry

· Increasing adoption of wearable drug delivery technologies

Challenges

· Availability of cheaper alternatives

· Challenges associated with manufacturing of prefilled syringes

Key Market Players

Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), West Pharmaceutical Services, Inc. (US), Baxter International Inc (US), Ompi (Italy), Catalent, Inc. (US), Weigao Group (China), Vetter Pharma International GmbH (Germany), Nipro Corporation (Japan), Elcam Medical (Israel), YPSOMED (Switzerland), Oval Medical Technologies (UK), SHL Medical AG (Switzerland), Terumo (Japan).

Request Sample Pages

North America accounted for the largest market share of the global prefilled syringes industry, by region in the forecast period. The pre-filled syringe market is anticipated to be dominated by the North American region due to a number of factors, including an advanced healthcare infrastructure, a high prevalence of chronic diseases, and a focus on patient safety and technological innovation. Its dominant position in the market is also a result of the region’s well-established pharmaceutical industry and rising demand for practical and precise drug delivery solutions. Furthermore, continued R&D expenditures and favorable regulatory environments in North America contribute to the expansion and use of pre-filled syringes.

Recent Developments

· In October 2018, Becton, Dickinson and Company launched the BD Intevi 1mL two-step disposable autoinjector.

· In July 2020, Becton, Dickinson and Company entered into an partnership with Biomedical Advanced Research and Development Authority (BARDA) (US)

· In July 2018, Becton, Dickinson and Company acquired Teva Medical Inc. (US)

Content Source:

[creativeera]

The Generic Sterile Injectables Market poised for strong growth driven by increasing demand for affordable healthcare

The generic sterile injectables market encompasses pharmaceutical formulations such as vials, ampoules, bottles, syringes and bags, which are administered parenterally into the body for treatments. They offer effective and affordable alternatives to branded sterile injectable drugs across therapeutic areas including oncology, cardiovascular diseases, infectious diseases and autoimmune diseases. The growing prevalence of chronic diseases and increasing healthcare expenditure have boosted the demand for generic sterile injectables globally.

The global generic sterile injectables market is estimated to be valued at US$ 46.33 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the generic sterile injectables market are Baxter International Inc., AstraZeneca plc, Merck and Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy's Laboratory, Mylan N.V., Sun Pharmaceutical Industries Ltd. The key players dominate the market with their wide array of products in various dosages. The increasing prevalence of chronic diseases and aging population has amplified the demand for affordable healthcare solutions. The rising healthcare costs have prompted patients and providers to shift towards cost-effective generic injectable drugs from branded equivalents. This has accelerated the growth of the global generic sterile injectables market. With rising healthcare expenditures, healthcare providers are boosting investments in emerging markets of Asia Pacific, Latin America, Middle East and Africa for expansion of their generic sterile injectables portfolio. Generic Sterile Injectables Market Trends is expected to drive during the forecast period. Market Key Trends Increased Research & Development and manufacturing capabilities of emerging players: With growing demand for affordable and effective biologics, emerging players are investing significantly in R&D and expanding their sterile injectables manufacturing infrastructure. This has led to increased competition and entry of more affordable biologics in the market.

Porter’s Analysis Threat of new entrants: Low barriers to entry make it easy for new companies to enter the market. However, regulations and requirement of high capital to set-up sterile facilities pose challenges. Bargaining power of buyers: Large group purchasing organizations and hospital networks have significant influence on prices. However, need for essential medicines keeps bargaining power in check. Bargaining power of suppliers: Few major global players supply key starting materials and APIs. However, potential for forward integration limits suppliers' bargaining power. Threat of new substitutes: Limited threat as generics have few major therapeutic substitutes. Biosimilars pose a potential long-term threat in certain disease segments. Competitive rivalry: Intense competition on pricing and new product development. Major players compete by improving quality, reliability of supply and enhancing portfolios. Frequent litigation and regulatory issues also impact competition. The United States dominates the Generic Sterile Injectables Market Regional Analysis accounting for over 40% revenue share in 2024. Strong payer system, sizable healthcare spending and increasing generic adoption to contain costs drive high growth. China sterile injectables market is projected to grow at over 12% till 2031, making it the fastest growing regional market. This can be attributed to rising living standards, healthcare reforms focusing on essential medicines and initiatives to expand domestic sterile manufacturing capabilities.

Get more insights on Generic Sterile Injectables Market

Get More Insights—Access the Report in the Language that Resonates with You

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )

[aimarketresearch]

Biosimilar Market Size, Share, Key Growth Drivers, Trends, Challenges and Competitive Landscape

Data Bridge Market research has recently issued comprehensive industry research on Global Biosimilar Market which includes growth analysis, regional marketing, challenges, opportunities, and drivers analysed in the report.

Besides, Biosimilar market report studies market growth opportunities and restraining factors. The geographical division of this market analysis report offers data that gives an idea of the revenue of the companies and sales figures of the market growth. The market report also contains the drivers and restraints for the Biosimilar market that are obtained with the help of SWOT analysis, and also shows all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands with their systemic company profiles, that are driving the market.

Data Bridge Market Research analyses that the global biosimilar market which was USD 37,270.20 million in 2022, is expected to reach USD 343,520.90 million by 2030, and is expected to undergo a CAGR of 32.00% during the forecast period 2023-2030. “Oncology” dominates the product segment of the global biosimilar market owing to the owing to the increase in number of research studies, increasing research and development activities by key players focused on oncology and advancements in healthcare technologies. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Access Full 350 Pages PDF Report @

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Key Questions Answered with this Study

1) What makes Biosimilar Market feasible for long term investment?

2) Know value chain areas where players can create value?

3) Teritorry that may see steep rise in CAGR & Y-O-Y growth?

4) What geographic region would have better demand for product/services?

5) What opportunity emerging territory would offer to established and new entrants in Biosimilar Market?

6) Risk side analysis connected with service providers?

7) How influencing factors driving the demand of Biosimilarin next few years?

8) What is the impact analysis of various factors in the Global Biosimilar Market growth?

9) What strategies of big players help them acquire share in mature market?

10) How Technology and Customer-Centric Innovation is bringing big Change in Biosimilar Market?

Some of the major players operating in the global biosimilar market are:

Novartis AG (Switzerland)

 Orion Pharma AB (Sweden)

 Pfizer Inc. (U.S.)

Samsung Bioepis. (South Korea)

 Coherus BioSciences, Inc. (U.S.)

 Amgen Inc. (U.S.)

Eli Lilly and Company (U.S.)

 Takeda Pharmaceutical Company Limited. (Japan)

 Bristol-Myers Squibb Company (U.S.)

 Merck KGaA (Germany)

 Teva Pharmaceutical Industries Ltd. (U.S.)

 Biocon. (India)

 Bayer AG (Germany)

 AbbVie Inc. (U.S.)

 Allergan (Ireland)

 Dr. Reddy’s Laboratories Ltd. (India)

 Boehringer Ingelheim International GmbH. (Germany)

 Biogen (U.S.)

Browse Trending Reports:

Vitamins Market

Triage B Type Natriuretic Peptide Bnp Testing Market

Healthcare Finance Solutions Market

Biosimilar Market

Surgical Instrument Tracking Systems Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com

[kenresearch1]

Top 5 players in US Biosimilar Market

Buy Now

STORY OUTLINE

Pfizer: Excelling in the line of Biosimilar drugs with an experience of more than 10 years with presence in over 180 countries.

Amgen: Making pharmaceutical products with an experience of over 40 years and presence in over 100 countries.

Viartis: Presence in over 165 countries, and making Biosimilar drugs in over 75 markets, this pharmaceutical company is another leading contributor of US Biosimilar market.

Coherus Biosciences: Increasing patient access to cost effective medicines with a Biosimilar drugs experience of 13 years.

Biogen: serving humanity through science with a experiences of more than 40 years in the field of biologics.

According to Ken Research, the US Biosimilar market is anticipated to grow at a CAGR of ~40% in the next five years which currently has a market size of ~USD 9.4 Bn.

The US Biosimilar market is rapidly growing and will be witnessing a significant growth in the next five years.

There are various reasons behind the rapid growth of US Biosimilar market. Some of the major reasons behind the growth of US Biosimilar market include the cost effective nature of Biosimilar drugs, rising geriatric population, rising prevalence of chronic diseases, and growing partnerships between companies to develop Biosimilar drugs.

Various companies and players are contributing to their best efforts in the growth of the US Biosimilar market.

This article aims to put light on the contributions done by the major players towards the growth of the US Biosimilar market.

1.Pfizer

Click to read more about Pfizer

Pfizer is a leading American pharmaceutical company which is operating in the field of generics or original drugs for more than 30 years. But did you know that this pharma not only manufactures biologics but also biosimilar drugs?

Pfizer has been in the business of biosimilar drugs for more than 10 years and have been quite successful as well. With more than 83,000 employees and presence in over 180 countries, this leading pharmaceutical company made almost USD 2 Bn. revenue only from its Biosimilar drugs sale in 2021.

Recently, this pharmaceutical company also collaborated with Samsung in two deals to produce various biosimilar drugs in South Korea. The deal size between these two companies happens to be approximately USD 900 Bn.

The major Biosimilar drugs of this pharmaceutical giant are primarily

ZIRABEV (a Biosimilar of Avastin)

TRAZIMERA (a Biosimilar of Herceptin)

RUXIENCE (a Biosimilar of Rituxan)

RITACRIT (a Biosimilar of Epogen)

NVYEPRIA (a Biosimilar of Neulasta)

NIVESTYM (a Biosimilar of Neupogen)

FILGRASTIM (a Biosimilar of Neupogen).

2.Amgen

Click here to Download a Sample Report

Amgen is another leading American pharmaceutical company which not only makes Biologics or generic drugs but also Biosimilar drugs. This pharmaceutical company has more than 40 years of experience when it comes to pharmaceutical line.

With over 25000 employees and presence in over 100 countries, this pharmaceutical company earned about USD 2 Bn. from their three biosimilar drugs which are reportedly MVASI, KANJITNTI, and AMJEVITA.

This pharma giant has also invested about USD 2 Bn. in the development of Biosimilar drugs.

This pharmaceutical company has made Biosimilar drugs primarily in 4 fields which are General Medicine, Oncology, and Hematology along with, Inflammation.

EPOTEIN ALFA

AMJEVITA

AVSOLA

KANJINTI

MVASI

RIABNI

are the various Biosimilar drugs of Amgen. And, STELARA, EYLEA, SOLIRIS are in their pipeline.

Recently Amgen revealed their Biosimilar report’s 8 version. It revealed a major information which said that the pharmaceutical company saved about USD 10 Bn. through their Biosimilar drugs in the past five years.

3.Viartis

Headquartered in Canonsburg, Pennsylvania, this American pharmaceutical company was founded only in 2020 yet they have achieved massive success in the pharmaceutical products with their revenue being USD 16 ~Bn. in 2022.

With presence in 165 countries and with over 45,000 employees worldwide, this pharmaceutical company makes pharmaceutical products in 10 areas which primarily are Cardiovascular, Dermatology, ophthalmology, Oncology, Gastroenterology, Women’s health, Infectious diseases, Diabetes & Metabolism, Immunology, CNS & Anesthesiology, Respiratory diseases and allergy.

Speaking of their first Biosimilar products, their first ever Biosimilar drug was launched in 2014. They have a variety of Biosimilar drugs which are primarily

TRASTUZUMAB

INSULIN ASPART

PEGFILGRASTIM

INSULIN GLARGINE-YFGN

ADALIMUMAB

BEVACIZUMAB

Their Biosimilar drug Insulin Glargine which is known as SEMGLEE was the first ever interchangeable Biosimilar drug in the United States which was FDA approved.

Their PEGFILGRASTIM also was the first ever FDA approved drug in the United States. They have launched their Biosimilar drugs in over 75 markets worldwide.

4.Coherus Biosciences:

Click here to Ask for a Custom Report

Headquartered in Redwood city, California this American pharmaceutical company earned a revenue of almost USD 211 Mn. In 2022.

With presence in over 55 countries and 300+ employees worldwide, this pharmaceutical company makes products in various areas such as solid tumors, non-small lung cancers, nasopharyngeal carcinoma, small cell lung cancer and hepatocellular carcinoma.

Speaking of their Biosimilar drugs, this pharma has been in the field of creating Biosimilar drugs since 2010 which has given them almost 13 years of experience.

This pharmaceutical company also disclosed that it plans to spend at least USD 1 Tn. on medicines worldwide, out of which at least 40% will be spent on Biosimilar drugs.

Their three major Biosimilar drugs which are also FDA approved include UDENCYA, YUSIMRY, and CIMERLI.

Udencya is a Biosimilar drug of Pegfilgrastim, Yusimry is a Biosimilar drug of Ranibizumab, and Cimerli is a Biosimilar drug of Adalimumab.

5.Biogen

Headquartered in Cambridge, Massachusetts, this American pharmaceutical company earned a revenue of around USD 10 Bn. in 2022.

This company happens to have an experience of more than 40 years when it comes to making pharmaceutical products.

With presence in over 80 countries and more than 9000 employees worldwide, this pharmaceutical company primarily deals in Neurology, Specialized Immunology, Neuropsychiatry, Ophthalmology, and Rare Diseases.

ADUCANUMAB

LECANEMAB

TOFERSEN

ZURANOLONE

LITIFILIMAB

BENAPALI

FLIXABI

IMRALDI

are some of their Biosimilar drugs.

With their Biosimilar drugs, more than 250,000 people have gone on Anti-Tumor Necrosis Factor therapy.

Recently, this pharmaceutical company also made an agreement with Bio-Thera solutions to develop a Biosimilar drug for the treatment of Rheumatoid Arthritis.

[adityarana1687-blog]

India Single-use Bioprocessing Probes And Sensors Market To Reach $191.0 Million By 2030

The India single-use bioprocessing probes and sensors market is anticipated to reach USD 191.0 million by 2030 and is anticipated to grow at a CAGR of 12.61% during the forecast period from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals and the growing popularity of disposable systems in preclinical trials are key factors driving the growth of the single-use bioprocessing probes and sensors market in India. The need for faster and more efficient drug development processes and the rising demand for personalized medicines contribute to the increased implementation of single-use bioprocessing systems.

The implementation of single-use technology (SUT) in biomanufacturing processes offers advantages such as reduced risk of cross-contamination and ensuring product purity and integrity, which is crucial for the growing domestic biosimilars and biologics market. It enhances operational efficiency, leading to shorter turnaround times and increased productivity - a key benefit for Indian manufacturers to scale and meet the rising domestic and global demand for biopharmaceuticals.

Furthermore, the commercial advantages of single-use sensors, such as streamlined operations, enhanced flexibility, and improved regulatory compliance and product quality, make them an attractive option for Indian biomanufacturers. The adoption of these technologies can help Indian companies lower their capital expenditure and achieve faster turnaround times.

Request a free sample copy or view report summary: India Single-use Bioprocessing Probes And Sensors Market Report

India Single-use Bioprocessing Probes And Sensors Market Report Highlights

The pH sensors type segment held the largest revenue share of 20.24% in 2023 and is expected to grow at the fastest CAGR over the forecast period. The growing demand for precise process monitoring, driven by the expanding biopharmaceutical industry, drives the adoption of single-use pH sensors. The oxygen sensors segment is expected to register a significant CAGR over the forecast period.

The upstream segment dominated the segment with a market share of 73.49% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. It is driven by the increasing demand for biopharmaceuticals and the need for efficient and cost-effective manufacturing processes.

The biopharmaceutical & pharmaceutical companies dominated the segment with a market share of 41.69% in 2023. The consistent introduction of new and innovative single-use bioprocessing probes and sensors is a key driver behind the growth of this market segment.

India Single-use Bioprocessing Probes And Sensors Market Segmentation

Grand View Research has segmented the India single-use bioprocessing probes and sensors market based on type, workflow, and end use:

India Single-use Bioprocessing Probes And Sensors Type Outlook (Revenue, USD Million, 2018 - 2030)

pH Sensor

Oxygen Sensors

Pressure Sensors

Temperature Sensors

Conductivity Sensors

Flow Meter & Sensors

Other Sensors

India Single-use Bioprocessing Probes And Sensors Workflow Outlook (Revenue, USD Million, 2018 - 2030)

Upstream

pH Sensor

Oxygen Sensors

Pressure Sensors

Temperature Sensors

Conductivity Sensors

Flow Meter & Sensors

Other Sensors

Downstream

pH Sensor

Pressure Sensors

Temperature Sensors

Conductivity Sensors

Flow Meter & Sensors

Other Sensors

India Single-use Bioprocessing Probes And Sensors End-use Outlook (Revenue, USD Million, 2018 - 2030)

Biopharmaceutical & Pharmaceutical Companies

CROs & CMOs

Academic & Research Institutes

Others

List of Key Players in theIndia Single-use Bioprocessing Probes And Sensors Market

Thermo Fisher Scientific

Sartorius AG

PreSens Precision Sensing GmbH

Hamilton Company

Mettler-Toledo India Private Limited

PARKER HANNIFIN CORP

Danaher

Saint-Gobain